Courtesy of Pharmboy
Visit Pharmboy here for his previous articles on pharm/biotech stocks and chapters in his TA book.
UK-based GlaxoSmithKline was ranked as the world’s fourth largest player in 2009 (behind US-based Pfizer, France-based Sanofi-Aventis and Switzerland-based Novartis) based on prescription pharma sales. The company was founded in 2000 via the merger of Glaxo Wellcome and SmithKline Beecham and is headquartered in Brentford, London, UK. I wrote about GSK in my first PSW write-up in 2009.
In terms of its therapeutic focus, GSK owes its market-leading position in the global respiratory market to the Glaxo Laboratories legacy. Over 30 years ago, Glaxo launched Ventolin for the treatment of asthma and developed and launched Serevent and Flixotide in 1990. A combination of these two compounds—sold under the brand names Seretide/Advair ($7.8B in 2009). Similarly, GSK’s origins in the CNS market—currently its third largest therapeutic area of focus—can be traced back to the Wellcome and SmithKline scientists. Other therapeutic areas of importance include infectious disease and virology (vaccines).
What GSK has done instead is sought to in-license product rights in order to boost the sales potential of its portfolio. Of the eight products launched by GSK since 2000, four have been in-licensed (Lexiva from Vertex, Levitra from Bayer, Boniva from Roche and Vesicare from Astellas). However, to date, none of these drugs have generated sales growth to make an impact on the company’s bottom-line. Furthermore, in response to Pfizer’s proposed acquisition of Wyeth (2009) and Merck & Co.’s merger with Schering-Plough (2009), GSK has inferred that it will not follow this route. (I think Gilmartin at his time at MRK said the same thing…he retired, and Boom). Instead CEO Andrew Witty says that GSK will continue to implement in-licensing and small acquisitive strategies (focused notably on emerging markets and driving diversification into generics) to support internal growth (hummm). GSK runs the risk of creating short-term benefit that compounds itself into a deficiency in the mid- to long-term if it fails to rectify its own shortcomings. – anotherwordds – big risks. This is because GSK chooses to partner with a smaller player that may not have strengths that complement GSK’s current weaknesses in term of portfolio fit or better yet, development foresight that limits or delays the progression of a compound through clinic.
Sales growth is going to come from two franchises for the next few years: Seretide/Advair (named Beyond Advair) and Avodart, respectively. Beyond Advair is essentially a once-daily version of Seretide/Advair (potentially the first once-daily ICS/LABA combination), while Duodart is a combination of Avodart and tamsulosin for the treatment of benign prostatic hyperplasia (BPH) – DNDN, hello!.
Many, many other drugs (> 20 by my last count) in the respiratory and neurosciences are in Phase II, so it is too early to tell where these will be, but we should have a better idea in a year or so about the companies prospects. There are a few very interesting and compelling targets/drugs, but those need to be reserved for after Phase II, as many things can happen between now and then.
With the higher dividend yield than its peers and a P/E a bit less than PFE, I like GSK bouncingi n this range for a while. Buying the stock for about $35 and selling the January 2012 puts for $5.50 and January 2012 calls for $3.30 gives a nice return 25% if called away, not including the dividend one collects along the way.